SCHEMBL6292239

SCHEMBL6292239

CCCC1=C(C#N)C(c2cccc3ccccc23)c2c[nH]nc2N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.40
MAPT P10636 4/20 0.40
KDM4E B2RXH2 3/20 0.40
CACNA1C Q13936 1/20 0.35
MET P08581 1/20 0.35
HSD17B10 Q99714 3/20 0.35
ALDH1A1 P00352 3/20 0.35
ALOX15 P16050 2/20 0.35
USP2 O75604 1/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
MYB P10242 7/20 0.34
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
LMNA P02545 2/20 0.32
RCE1 Q9Y256 1/20 0.32
BRCA1 P38398 1/20 0.32
HBB P68871 1/20 0.32
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6296757 0.86 ALDH1A1 (0.43) NR3C2MAPTKDM4EMETHSD17B10
SCHEMBL6297368 0.86 HSD17B10 (0.36) NR3C2MAPTKDM4EMETHSD17B10
SCHEMBL6292466 0.85 ALDH1A1 (0.40) NR3C2MAPTKDM4EHSD17B10ALDH1A1
SCHEMBL6297230 0.84 ALDH1A1 (0.53) NR3C2MAPTKDM4EHSD17B10ALDH1A1
SCHEMBL6297233 0.83 ALDH1A1 (0.36) NR3C2MAPTKDM4EHSD17B10ALDH1A1
SCHEMBL6296586 0.83 ALDH1A1 (0.35) NR3C2MAPTKDM4EMETHSD17B10
SCHEMBL6292345 0.82 CUL4A (0.47) NR3C2MAPTKDM4ECACNA1CHSD17B10
SCHEMBL6296675 0.82 NR3C2 (0.33) NR3C2MAPTKDM4EMETHSD17B10
SCHEMBL6760910 0.82 NR3C2 (0.33) NR3C2MAPTKDM4EMETHSD17B10
SCHEMBL6292297 0.81 ALDH1A1 (0.38) NR3C2MAPTKDM4EMETHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB NR3C2 2858/4885MAPT 96/4885KDM4E 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.